Whanin Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Whanin Pharm makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies across South Korea.
The company is listed on KOSPI, South Korea's main stock exchange. Its filing covers a broad portfolio of pharmaceutical products alongside active research and development activity, suggesting the business spans both established medicines and pipeline compounds.
Summary is AI-generated and may contain errors · figures from DART filings
Whanin Pharm in five facts
What does Whanin Pharm do?
Whanin Pharm makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies across South Korea.
Where is Whanin Pharm listed and in which sector?
Whanin Pharm (Korean name: 환인제약) trades under KRX code 016580 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Whanin Pharm?
Its market capitalisation was US$145.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Whanin Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Whanin Pharm reported revenue of US$192.6M, operating profit of US$9.8M and net income of US$10.3M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 1.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
Whanin Pharm filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$49.5M (+11.4% year on year), operating profit of US$5.47M (+192.3% year on year) and net income of US$5.3M (+140% year on year).
Earnings · Jul 29 - Operating results (consolidated) (preliminary) (fair disclosure)
Whanin Pharm filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$48.3M (+18.2% year on year), operating profit of US$6.37M (+77.7% year on year) and net income of US$5.07M (+45.8% year on year).
Earnings · Apr 27 - Cash/in-kind dividend decision
Whanin Pharm declared a cash dividend of US$0.21 per share, equal to about 2.5% of the recent share price.
Dividend · Mar 3 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Whanin Pharm reported consolidated results for FY2025: revenue of US$177M (−1.7% year on year), operating profit of US$9.04M (−39.4% year on year) and net income of US$9.44M (−41.9% year on year).
Earnings · Feb 13